In addition to greatly increased risk of AD, APOE4 carriers are at risk for poor neurological outcomes in other contexts, including chronic processes of Diffuse Lewy Body disease (Guerreiro et al., 2018) and tauopathy (Shi et al., 2017), and of more acute conditions like complications from COVID19 (Safdari Lord et al., 2022) or chemotherapy (Mandelblatt et al., 2018). Here, APOE is linked to tauopathy.